Across TCGA pan-cancer cohorts, SLC48A1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SLC48A1 data layer compared with 22 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher SLC48A1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC48A1 expression acts as an unfavorable survival marker.
COAD are the cancer types where SLC48A1 Mutation most reproducibly stratifies survival.